Study details
Enrolling now
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Theravectys S.A.
NCT IDNCT06319963ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
72
Study length
about 2.4 years
Ages
18+
Locations
4 sites in FL, OK
What this study is about
This trial is testing the safety and effectiveness of a new treatment called Lenti-HPV-07 in people with cancer caused by Human Papilloma Virus (HPV). Participants will receive either one or two injections of Lenti-HPV-07, followed by up to 1 year of follow-up visits.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive One IM injection Lenti-HPV-07
- 2.Receive Two IM injections Lenti-HPV-07
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
injection
Endpoints
Primary: Safety and Tolerability
Secondary: Immunogenicity, PD-L1 expression
Body systems
Oncology